Header Logo

Philip Bonomi

TitleProfessor
InstitutionRush University, Rush Medical College
DepartmentInternal Medicine, Division of Hematology/Oncology/Cell Therapy
Address
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus ID is 7005792843

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Zhou YM, Shin J, Jelinek M, Fidler MJ, Batus M, Bonomi PD, Marwaha G. Four-Phase, Definitive Chemoradiation for a Real-World (Poor Risk and/or Elderly) Patient Population With Locally Advanced Non-small Cell Lung Cancer. Cureus. 2022 Sep; 14(9):e29423. PMID: 36299962.
      Citations:    
    2. Hemu M, Chiang CJ, Bhatt PK, Ahmed A, Hein KZ, Mourad T, Randall ME, Palomo AP, Kramer JB, Fughhi I, Fogg L, Bonomi P, Okwuosa TM. Associations between sinus tachycardia and adverse cardiovascular outcomes and mortality in cancer patients. J Thorac Dis. 2021 Aug; 13(8):4845-4852. PMID: 34527323.
      Citations:    
    3. Yun NK, Rouhani SJ, Bestvina CM, Ritz EM, Gilmore BA, Tarhoni I, Borgia JA, Batus M, Bonomi PD, Fidler MJ. Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy. Cancers (Basel). 2021 Mar 20; 13(6). PMID: 33804721.
      Citations:    
    4. Tarhoni I, Wakefield CJ, Kollipara R, Fidler MJ, Batus M, Bonomi P, Borgia JA. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition. J Immunol Methods. 2021 03; 490:112956. PMID: 33434603.
      Citations:    
    5. Leal TA, Argento AC, Bhadra K, Hogarth DK, Grigorieva J, Hartfield RM, McDonald RC, Bonomi PD. Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis. Curr Med Res Opin. 2020 09; 36(9):1497-1505. PMID: 32615813.
      Citations:    
    6. Bonomi P, Stuccio N, Delgra CJ, Chuk MK, Spira A, Deitz AC, Blumenthal GM, Ferris A, Gong Y, He J, Basu Roy U, Selig W. Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cancer. Ther Innov Regul Sci. 2020 09; 54(5):1208-1214. PMID: 32865803.
      Citations:    
    7. Forde PM, Bonomi P, Shaw A, Blumenthal GM, Ferris A, Patel C, Melemed A, Basu Roy U, Ramamoorthy A, Liu Q, Burns T, Gainor JF, Lovly C, Piotrowska Z, Lehman J, Selig W. Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group. Clin Lung Cancer. 2020 07; 21(4):295-307. PMID: 32201247.
      Citations:    
    8. Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA. Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer Discov. 2020 01; 10(1):40-53. PMID: 31732494.
      Citations:    
    9. Bonomi P, Fidler MJ, Shah P, Borgia J. Theoretical and Practical Implications of Treating Cachexia in Advanced Lung Cancer Patients. Cancers (Basel). 2019 Oct 23; 11(11). PMID: 31652685.
      Citations:    
    10. Fidler MJ, Borgia JA, Bonomi PD, Shah P. Prognostic Significance of Skeletal Muscle Loss During Early Postoperative Period in Elderly Patients with Esophageal Cancer. Ann Surg Oncol. 2019 Nov; 26(12):3807-3808. PMID: 31471841.
      Citations:    
    11. Marcoux N, Gettinger SN, O'Kane G, Arbour KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi PD, Del Prete S, Wurtz A, Farago AF, Dias-Santagata D, Mino-Kenudson M, Reckamp KL, Yu HA, Wakelee HA, Shepherd FA, Piotrowska Z, Sequist LV. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol. 2019 02 01; 37(4):278-285. PMID: 30550363.
      Citations:    
    12. Peters S, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, Baik CS, Isla D, Carpeno JC, Garrido P, Rittmeyer A, Tiseo M, Meyenberg C, de Haas S, Lam LH, Lu MW, Stinchcombe TE. Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. Clin Cancer Res. 2019 01 01; 25(1):64-72. PMID: 30206164.
      Citations:    
    13. Bonomi PD, Gandara D, Hirsch FR, Kerr KM, Obasaju C, Paz-Ares L, Bellomo C, Bradley JD, Bunn PA, Culligan M, Jett JR, Kim ES, Langer CJ, Natale RB, Novello S, P?rol M, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Vansteenkiste JF, Wakelee H, Thatcher N. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. Ann Oncol. 2018 08 01; 29(8):1701-1709. PMID: 29905778.
      Citations:    
    14. Gadgeel SM, Pennell NA, Fidler MJ, Halmos B, Bonomi P, Stevenson J, Schneider B, Sukari A, Ventimiglia J, Chen W, Galasso C, Wozniak A, Boerner J, Kalemkerian GP. Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). J Thorac Oncol. 2018 09; 13(9):1393-1399. PMID: 29775808.
      Citations:    
    15. Bonomi P, Blumenthal G, Ferris AS, Stewart DJ, Selig WKD, Krug LM, Allen J, Ison G, Langer CJ, Melemed A, Odogwu L, Basu Roy U, Sandler A. Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria. J Thorac Oncol. 2018 06; 13(6):748-751. PMID: 29793646.
      Citations:    
    16. Hirsch FR, Kerr KM, Bunn PA, Kim ES, Obasaju C, P?rol M, Bonomi P, Bradley JD, Gandara D, Jett JR, Langer CJ, Natale RB, Novello S, Paz-Ares L, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Stinchcombe TE, Vansteenkiste JF, Wakelee H, Thatcher N. Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. Clin Lung Cancer. 2018 07; 19(4):331-339. PMID: 29773328.
      Citations:    
    17. Fidler MJ, Fhied CL, Roder J, Basu S, Sayidine S, Fughhi I, Pool M, Batus M, Bonomi P, Borgia JA. The serum-based VeriStrat? test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. BMC Cancer. 2018 03 20; 18(1):310. PMID: 29558888.
      Citations:    
    18. Tarhoni I, Fhied CL, Pool M, Liptay MJ, Bonomi P, Seder CW, Borgia JA. Development of bead based multiplexed immunoassay for evaluation of midkine, syndecan-1, and ANGPTL4 in patient serum. J Immunoassay Immunochem. 2018; 39(1):84-98. PMID: 29309212.
      Citations:    
    19. Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn PA, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, P?rol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Wakelee H, Thatcher N. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. J Thorac Oncol. 2018 02; 13(2):165-183. PMID: 29175116.
      Citations:    
    20. Fidler MJ, Frankenberger C, Seto R, Lobato GC, Fhied CL, Sayidine S, Basu S, Pool M, Karmali R, Batus M, Lie WR, Hayes D, Mistry J, Bonomi P, Borgia JA. Differential expression of circulating biomarkers of tumor phenotype and outcomes in previously treated non-small cell lung cancer patients receiving erlotinib vs. cytotoxic chemotherapy. Oncotarget. 2017 Aug 29; 8(35):58108-58121. PMID: 28938541.
      Citations:    
    21. Bonomi P, Batus M, Fidler MJ, Borgia JA. Practical and theoretical implications of weight gain in advanced non-small cell lung cancer patients. Ann Transl Med. 2017 Mar; 5(6):152. PMID: 28462232.
      Citations:    
    22. Derman BA, Macklis JN, Azeem MS, Sayidine S, Basu S, Batus M, Esmail F, Borgia JA, Bonomi P, Fidler MJ. Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer. BMC Cancer. 2017 02 16; 17(1):141. PMID: 28209123.
      Citations:    
    23. Cooper DS, Meriggioli MN, Bonomi PD, Malik R. Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy. J Neuromuscul Dis. 2017; 4(2):169-173. PMID: 28505981.
      Citations:    
    24. Awad MM, Chu QS, Gandhi L, Stephenson JJ, Govindan R, Bradford DS, Bonomi PD, Ellison DM, Eaton KD, Fritsch H, Munzert G, Johnson BE, Socinski MA. An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). Lung Cancer. 2017 02; 104:126-130. PMID: 28212994.
      Citations:    
    25. Langer CJ, Obasaju C, Bunn P, Bonomi P, Gandara D, Hirsch FR, Kim ES, Natale RB, Novello S, Paz-Ares L, P?rol M, Reck M, Ramalingam SS, Reynolds CH, Socinski MA, Spigel DR, Wakelee H, Mayo C, Thatcher N. Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. J Thorac Oncol. 2016 12; 11(12):2066-2081. PMID: 27575423.
      Citations:    
    26. Waqar SN, Bonomi PD, Govindan R, Hirsch FR, Riely GJ, Papadimitrakopoulou V, Kazandjian D, Khozin S, Larkins E, Dickson DJ, Malik S, Horn L, Ferris A, Shaw AT, J?nne PA, Mok TS, Herbst R, Keegan P, Pazdur R, Blumenthal GM. Clinician Perspectives on Current Issues in Lung Cancer Drug Development. J Thorac Oncol. 2016 09; 11(9):1387-96. PMID: 27401214.
      Citations:    
    27. Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn P, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, P?rol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Stinchcombe TE, Wakelee H, Mayo C, Thatcher N. Clinicopathologic Features of Advanced Squamous NSCLC. J Thorac Oncol. 2016 09; 11(9):1411-22. PMID: 27296106.
      Citations:    
    28. Patel JD, Pereira JR, Chen J, Liu J, Guba SC, John WJ, Orlando M, Scagliotti G, Bonomi PD. Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients. Ann Oncol. 2016 08; 27(8):1612-9. PMID: 27217544.
      Citations:    
    29. Reck M, Socinski MA, Luft A, Szczesna A, Dediu M, Ramlau R, Losonczy G, Molinier O, Schumann C, Gralla RJ, Bonomi P, Brown J, Soldatenkova V, Chouaki N, Obasaju C, Peterson P, Thatcher N. The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial. J Thorac Oncol. 2016 Jun; 11(6):808-18. PMID: 26980471.
      Citations:    
    30. Dandekar VK, Young J, Kiel K, Bonomi P, Fidler MJ, Batus M, Sher DJ. Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer. Am J Clin Oncol. 2015 Dec; 38(6):605-9. PMID: 24781341.
      Citations:    
    31. Derman BA, Mileham KF, Bonomi PD, Batus M, Fidler MJ. Treatment of advanced squamous cell carcinoma of the lung: a review. Transl Lung Cancer Res. 2015 Oct; 4(5):524-32. PMID: 26629421.
      Citations:    
    32. Ziel E, Hermann G, Sen N, Bonomi P, Liptay MJ, Fidler MJ, Batus M, Warren WH, Chmielewski G, Sher DJ. Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0-2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response. J Thorac Oncol. 2015 Oct; 10(10):1475-80. PMID: 26398822.
      Citations:    
    33. O'Mahony S, Nathan S, Mohajer R, Bonomi P, Batus M, Fidler MJ, Wells K, Kern N, Sims S, Amin D. Survival Prediction in Ambulatory Patients With Stage III/IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale. Am J Hosp Palliat Care. 2016 May; 33(4):374-80. PMID: 25670717.
      Citations:    
    34. Spigel DR, Patel JD, Reynolds CH, Garon EB, Hermann RC, Govindan R, Olsen MR, Winfree KB, Chen J, Liu J, Guba SC, Socinski MA, Bonomi P. Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015 Feb; 10(2):353-9. PMID: 25611228.
      Citations:    
    35. Reynolds CH, Patel JD, Garon EB, Olsen MR, Bonomi P, Govindan R, Pennella EJ, Liu J, Guba SC, Li S, Spigel DR, Hermann RC, Socinski MA, Obasaju CK. Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by?Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2015 May; 16(3):200-8. PMID: 25516338.
      Citations:    
    36. Doebele RC, Spigel D, Tehfe M, Thomas S, Reck M, Verma S, Eakle J, Bustin F, Goldschmidt J, Cao D, Alexandris E, Yurasov S, Camidge DR, Bonomi P. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer. 2015 Mar 15; 121(6):883-92. PMID: 25377507.
      Citations:    
    37. Daly S, Kubasiak JC, Rinewalt D, Pithadia R, Basu S, Fhied C, Lobato GC, Seder CW, Hong E, Warren WH, Chmielewski G, Liptay MJ, Bonomi P, Borgia JA. Circulating angiogenesis biomarkers are associated with disease progression in lung adenocarcinoma. Ann Thorac Surg. 2014 Dec; 98(6):1968-75; discussion 1975. PMID: 25301368.
      Citations:    
    38. Somaiah N, Fidler MJ, Garrett-Mayer E, Wahlquist A, Shirai K, Buckingham L, Hensing T, Bonomi P, Simon GR. Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung. Oncoscience. 2014; 1(8):522-528. PMID: 25594059.
      Citations:    
    39. Garg S, Gielda BT, Kiel K, Turian JV, Fidler MJ, Batus M, Bonomi P, Sher DJ. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy. Pract Radiat Oncol. 2014 Sep-Oct; 4(5):342-348. PMID: 25194104.
      Citations:    
    40. Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013 Dec 01; 31(34):4349-57. PMID: 24145346.
      Citations:    
    41. Sutton P, Borgia JA, Bonomi P, Plate JM. Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells. Mol Cancer. 2013 Jul 16; 12:76. PMID: 23866081.
      Citations:    
    42. Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, Webb T, Harper H, Huberman M, Ramalingam S, Wong KK, Teofilovici F, Guo W, Shapiro GI. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013 Jun 01; 19(11):3068-77. PMID: 23553849.
      Citations:    
    43. Bonomi PD, Mace J, Mandanas RA, Min M, Olsen M, Youssoufian H, Katz TL, Sheth G, Lee HJ. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol. 2013 Mar; 8(3):338-45. PMID: 23370316.
      Citations:    
    44. Sher DJ, Gielda BT, Liptay MJ, Warren WH, Batus M, Fidler MJ, Garg S, Bonomi P. Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2013 Jul; 14(4):370-5. PMID: 23260389.
      Citations:    
    45. Bradly DP, Gattuso P, Pool M, Basu S, Liptay M, Bonomi P, Buckingham L. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Diagn Mol Pathol. 2012 Dec; 21(4):207-13. PMID: 23111194.
      Citations:    
    46. Garg S, Gielda BT, Turian JV, Liptay M, Warren WH, Bonomi P, Sher DJ. Patterns of regional failure in stage III non-small cell lung cancer treated with neoadjuvant chemoradiation therapy and resection. Pract Radiat Oncol. 2013 Oct-Dec; 3(4):287-93. PMID: 24674400.
      Citations:    
    47. Edelman MJ, Harb WA, Pal SE, Boccia RV, Kraut MJ, Bonomi P, Conley BA, Rogers JS, Messmann RA, Garon EB. Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung. J Thorac Oncol. 2012 Oct; 7(10):1618-21. PMID: 22982661.
      Citations:    
    48. Fidler MJ, Basu S, Buckingham L, Walters K, McCormack S, Batus M, Coon J, Bonomi P. Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer. Anticancer Res. 2012 May; 32(5):1705-10. PMID: 22593449.
      Citations:    
    49. Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, Chu Q, Giaccone G, Khaira D, Ramalingam SS, Ranson MR, Dive C, McKeegan EM, Chyla BJ, Dowell BL, Chakravartty A, Nolan CE, Rudersdorf N, Busman TA, Mabry MH, Krivoshik AP, Humerickhouse RA, Shapiro GI, Gandhi L. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012 Jun 01; 18(11):3163-9. PMID: 22496272.
      Citations:    
    50. Fidler MJ, Shersher DD, Borgia JA, Bonomi P. Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls. Ther Adv Med Oncol. 2012 Mar; 4(2):51-60. PMID: 22423264.
      Citations:    
    51. Fidler MJ, Morrison LE, Basu S, Buckingham L, Walters K, Batus M, Jacobson KK, Jewell SS, Coon J, Bonomi PD. PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy. Br J Cancer. 2011 Dec 06; 105(12):1920-6. PMID: 22095222.
      Citations:    
    52. Shersher DD, Vercillo MS, Fhied C, Basu S, Rouhi O, Mahon B, Coon JS, Warren WH, Faber LP, Hong E, Bonomi P, Liptay MJ, Borgia JA. Biomarkers of the insulin-like growth factor pathway predict progression and outcome in lung cancer. Ann Thorac Surg. 2011 Nov; 92(5):1805-11; discussion 1811. PMID: 21945224.
      Citations:    
    53. Gielda BT, Marsh JC, Zusag TW, Faber LP, Liptay M, Basu S, Warren WH, Fidler MJ, Batus M, Abrams RA, Bonomi P. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol. 2011 Jun; 6(6):1079-86. PMID: 21532501.
      Citations:    
    54. Kim AW, Liptay MJ, Bonomi P, Warren WH, Basu S, Farlow EC, Faber LP. Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. Ann Thorac Surg. 2011 Jul; 92(1):233-41; discussion 241-3. PMID: 21620372.
      Citations:    
    55. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011 Mar 01; 29(7):909-16. PMID: 21282543.
      Citations:    
    56. Bonomi P. Lung cancer: new developments point the way to reduced mortality. Oncology (Williston Park). 2011 Jan; 25(1):82, 84. PMID: 21361248.
      Citations:    
    57. Bonomi P. Epidermal growth factor receptor pathway. J Thorac Oncol. 2010 Dec; 5(12 Suppl 6):S470-1. PMID: 21102243.
      Citations:    
    58. Patel K, Farlow EC, Kim AW, Lee BS, Basu S, Coon JS, DeCresce D, Thimothy L, Walters KA, Fhied C, Chang C, Chen SH, Faber LP, Bonomi P, Liptay MJ, Borgia JA. Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers. Int J Cancer. 2011 Jul 01; 129(1):133-42. PMID: 20824709.
      Citations:    
    59. Gielda BT, Mehta P, Khan A, Marsh JC, Zusag TW, Warren WH, Fidler MJ, Abrams RA, Bonomi P, Liptay M, Faber LP. Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):985-91. PMID: 20932684.
      Citations:    
    60. Batus M, Fidler MJ, Bonomi PD. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Expert Rev Anticancer Ther. 2010 Oct; 10(10):1589-99. PMID: 20942630.
      Citations:    
    61. Farlow EC, Vercillo MS, Coon JS, Basu S, Kim AW, Faber LP, Warren WH, Bonomi P, Liptay MJ, Borgia JA. A multi-analyte serum test for the detection of non-small cell lung cancer. Br J Cancer. 2010 Oct 12; 103(8):1221-8. PMID: 20859284.
      Citations:    
    62. Farlow EC, Patel K, Basu S, Lee BS, Kim AW, Coon JS, Faber LP, Bonomi P, Liptay MJ, Borgia JA. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res. 2010 Jul 01; 16(13):3452-62. PMID: 20570928.
      Citations:    
    63. Kim AW, Batus M, Myint R, Fidler MJ, Basu S, Bonomi P, Faber LP, Wightman SC, Warren WH, McIntire M, Arvanitis LD, Gattuso P, Xu X, Liptay MJ. Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer. Lung Cancer. 2011 Feb; 71(2):186-90. PMID: 20570389.
      Citations:    
    64. Buckingham L, Penfield Faber L, Kim A, Liptay M, Barger C, Basu S, Fidler M, Walters K, Bonomi P, Coon J. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer. 2010 Apr 01; 126(7):1630-9. PMID: 19795445.
      Citations:    
    65. Bonomi PD. Implications of key trials in advanced nonsmall cell lung cancer. Cancer. 2010 Mar 01; 116(5):1155-64. PMID: 20087963.
      Citations:    
    66. Bonomi P. Apoptosis. J Thorac Oncol. 2009 Nov; 4(11 Suppl 3):S1061-2. PMID: 19861917.
      Citations:    
    67. Kim AW, Faber LP, Warren WH, Basu S, Wightman SC, Weber JA, Bonomi P, Liptay MJ. Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does "side" really matter? Ann Thorac Surg. 2009 Sep; 88(3):937-43; discussion 944. PMID: 19699924.
      Citations:    
    68. Lilenbaum R, Villaflor VM, Langer C, O'Byrne K, O'Brien M, Ross HJ, Socinski M, Oldham FB, Sandilac L, Singer JW, Bonomi P. Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. J Thorac Oncol. 2009 Jul; 4(7):869-74. PMID: 19487960.
      Citations:    
    69. Fidler MJ, Kim AW, Zusag T, Bonomi P. Treatment of locally advanced non-small cell lung cancer. Clin Adv Hematol Oncol. 2009 Jul; 7(7):455-64, 479-80. PMID: 19701153.
      Citations:    
    70. Patel JD, Bonomi P, Socinski MA, Govindan R, Hong S, Obasaju C, Pennella EJ, Girvan AC, Guba SC. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer. 2009 Jul; 10(4):252-6. PMID: 19632943.
      Citations:    
    71. Gerena-Lewis M, Crawford J, Bonomi P, Maddox AM, Hainsworth J, McCune DE, Shukla R, Zeigler H, Hurtubise P, Chowdhury TR, Fletcher B, Dyehouse K, Ghalie R, Jazieh AR. A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer. Am J Clin Oncol. 2009 Jun; 32(3):269-73. PMID: 19433964.
      Citations:    
    72. Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, Bonomi PD. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009 Jul 10; 27(20):3284-9. PMID: 19433684.
      Citations:    
    73. Borgia JA, Basu S, Faber LP, Kim AW, Coon JS, Kaiser-Walters KA, Fhied C, Thomas S, Rouhi O, Warren WH, Bonomi P, Liptay MJ. Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer. J Thorac Oncol. 2009 Mar; 4(3):338-47. PMID: 19190517.
      Citations:    
    74. Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, Ranade AA, Cohen G, Trigo JM, Sandler AB, Bonomi PD, Herbst RS, Krebs AD, Vasselli J, Johnson BE. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2008 Nov 20; 26(33):5407-15. PMID: 18936474.
      Citations:    
    75. Paz-Ares L, Ross H, O'Brien M, Riviere A, Gatzemeier U, Von Pawel J, Kaukel E, Freitag L, Digel W, Bischoff H, Garc?a-Campelo R, Iannotti N, Reiterer P, Bover I, Prendiville J, Eisenfeld AJ, Oldham FB, Bandstra B, Singer JW, Bonomi P. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer. 2008 May 20; 98(10):1608-13. PMID: 18475293.
      Citations:    
    76. Einhorn LH, Bonomi P, Bunn PA, Camidge DR, Carbone DP, Choy H, Dubinett SM, Gandara DR, Gaspar LE, Govindan R, Johnson DH, Minna JD, Scagliotti G, West HJ, Herbst RS. Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. J Thorac Oncol. 2008 May; 3(5):545-55. PMID: 18449013.
      Citations:    
    77. Fidler MJ, Argiris A, Patel JD, Johnson DH, Sandler A, Villaflor VM, Coon J, Buckingham L, Kaiser K, Basu S, Bonomi P. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res. 2008 Apr 01; 14(7):2088-94. PMID: 18381949.
      Citations:    
    78. Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, Lo L, Gallant G, Klein J. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer. 2008 Jul; 61(1):82-90. PMID: 18255187.
      Citations:    
    79. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol. 2007 Oct 20; 25(30):4743-50. PMID: 17909199.
      Citations:    
    80. J?nne PA, von Pawel J, Cohen RB, Crino L, Butts CA, Olson SS, Eiseman IA, Chiappori AA, Yeap BY, Lenehan PF, Dasse K, Sheeran M, Bonomi PD. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. J Clin Oncol. 2007 Sep 01; 25(25):3936-44. PMID: 17761977.
      Citations:    
    81. Bonomi PD, Buckingham L, Coon J. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 2):s4606-12. PMID: 17671150.
      Citations:    
    82. Lynch TJ, Bonomi PD, Butts C, Davies AM, Engelman J, Govindan R, Herbst RS, Heymach JV, Johnson BE, Martins RG, Perez-Soler R, Riely GJ, Sandler AB, Sequist LV, Socinski MA, Wong KK, Hart CS. Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 2):s4583-8. PMID: 17671145.
      Citations:    
    83. Vansteenkiste J, Lara PN, Le Chevalier T, Breton JL, Bonomi P, Sandler AB, Socinski MA, Delbaldo C, McHenry B, Lebwohl D, Peck R, Edelman MJ, Edelman M. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol. 2007 Aug 10; 25(23):3448-55. PMID: 17606973.
      Citations:    
    84. Buckingham LE, Coon JS, Morrison LE, Jacobson KK, Jewell SS, Kaiser KA, Mauer AM, Muzzafar T, Polowy C, Basu S, Gale M, Villaflor VM, Bonomi P. The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib. J Thorac Oncol. 2007 May; 2(5):414-22. PMID: 17473657.
      Citations:    
    85. Bonomi P. Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer. Expert Rev Anticancer Ther. 2007 Apr; 7(4):415-22. PMID: 17428162.
      Citations:    
    86. Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, J?nne PA, Bonomi P. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol. 2006 Nov 20; 24(33):5253-8. PMID: 17114658.
      Citations:    
    87. Pitler LR, Bonomi PD. Developing an effective and compliant plan for billing clinical trials. J Oncol Pract. 2006 Nov; 2(6):265-7. PMID: 20859352.
      Citations:    
    88. Khan AJ, Mehta PS, Zusag TW, Bonomi PD, Penfield Faber L, Shott S, Abrams RA. Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiother Oncol. 2006 Nov; 81(2):163-7. PMID: 17050016.
      Citations:    
    89. Treat J, Bonomi P, McCleod M, Christiansen NP, Mintzer DM, Monberg MJ, Ye Z, Chen R, Obasaju CK. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial. Lung Cancer. 2006 Jul; 53(1):77-83. PMID: 16730854.
      Citations:    
    90. Gollob JA, Bonomi P. Historic evidence and future directions in clinical trial therapy of solid tumors. Oncology (Williston Park). 2006 May; 20(6 Suppl 5):10-8. PMID: 16773840.
      Citations:    
    91. Albain KS, Belani CP, Bonomi P, O'Byrne KJ, Schiller JH, Socinski M. PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2. Clin Lung Cancer. 2006 May; 7(6):417-9. PMID: 16800969.
      Citations:    
    92. Villaflor V, Bonomi P. Other compounds and targets in non-small cell lung cancer. Semin Oncol. 2005 Dec; 32(6 Suppl 10):S30-6. PMID: 16459177.
      Citations:    
    93. Bonomi PD. Current strategies in the management of lung cancer. Oncology (Williston Park). 2005 Nov; 19(13):1667-8. PMID: 16425520.
      Citations:    
    94. Hassaballa HA, Cohen ES, Khan AJ, Ali A, Bonomi P, Rubin DB. Positron emission tomography demonstrates radiation-induced changes to nonirradiated lungs in lung cancer patients treated with radiation and chemotherapy. Chest. 2005 Sep; 128(3):1448-52. PMID: 16162742.
      Citations:    
    95. Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005 Sep 01; 23(25):5883-91. PMID: 16087941.
      Citations:    
    96. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol. 2005 Jan 01; 23(1):175-83. PMID: 15625371.
      Citations:    
    97. Bonomi PD. Therapeutic advances in second-line treatment of advanced non-small-cell lung cancer. Clin Lung Cancer. 2004 Nov; 6(3):154-61. PMID: 15555216.
      Citations:    
    98. Weinberg R, Kaurin DG, Choy H, Curran WJ, MacRae R, Kim JS, Kim J, Tucker SL, Bonomi PD, Belani C, Starkschall G. Dosimetric uncertainties of three-dimensional dose reconstruction from two-dimensional data in a multi-institutional study. J Appl Clin Med Phys. 2004; 5(4):15-28. PMID: 15738918.
      Citations:    
    99. Choy H, Bonomi PD. Locally advanced NSCLC: current state of the art, treatment and future directions. J Natl Compr Canc Netw. 2004 Sep; 2 Suppl 2:S23-30. PMID: 19780243.
      Citations:    
    100. P?rez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santab?rbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol. 2004 Aug 15; 22(16):3238-47. PMID: 15310767.
      Citations:    
    101. Extermann M, Bonetti M, Sledge GW, O'Dwyer PJ, Bonomi P, Benson AB. MAX2--a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials. Eur J Cancer. 2004 May; 40(8):1193-8. PMID: 15110883.
      Citations:    
    102. Leslie WT, Bonomi PD. Novel treatments in non-small cell lung cancer. Hematol Oncol Clin North Am. 2004 Feb; 18(1):245-67. PMID: 15005292.
      Citations:    
    103. Bonomi PD. Epidermal growth factor receptor-targeted therapy and symptom improvement in non-small cell lung cancer. Am J Health Syst Pharm. 2003 Dec 15; 60(24 Suppl 9):S16-21. PMID: 14717024.
      Citations:    
    104. Anderson KM, Bonomi P, Hu Y, Harris JE. An interaction between type 1 and type 2 programmed cell death and clonogenic survival. Med Hypotheses. 2003 Nov-Dec; 61(5-6):583-5. PMID: 14592791.
      Citations:    
    105. Anderson KM, Alrefai W, Bonomi P, Seed TM, Dudeja P, Hu Y, Harris JE. Caspase-dependent and -independent panc-1 cell death due to actinomycin D and MK 886 are additive but increase clonogenic survival. Exp Biol Med (Maywood). 2003 Sep; 228(8):915-25. PMID: 12968063.
      Citations:    
    106. Bonomi P. Clinical studies with non-iressa EGFR tyrosine kinase inhibitors. Lung Cancer. 2003 Aug; 41 Suppl 1:S43-8. PMID: 12867061.
      Citations:    
    107. Bonomi P. Erlotinib: a new therapeutic approach for non-small cell lung cancer. Expert Opin Investig Drugs. 2003 Aug; 12(8):1395-401. PMID: 12882624.
      Citations:    
    108. Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol. 2003 Apr 15; 21(8):1536-43. PMID: 12697878.
      Citations:    
    109. Treat J, Schiller J, Quoix E, Mauer A, Edelman M, Modiano M, Bonomi P, Ramlau R, Lemarie E. ZD0473 treatment in lung cancer: an overview of the clinical trial results. Eur J Cancer. 2002 Dec; 38 Suppl 8:S13-8. PMID: 12645908.
      Citations:    
    110. Cella D, Eton DT, Fairclough DL, Bonomi P, Heyes AE, Silberman C, Wolf MK, Johnson DH. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 2002 Mar; 55(3):285-95. PMID: 11864800.
      Citations:    
    111. Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 4):78-86. PMID: 11894017.
      Citations:    
    112. Anderson KM, Alrefai W, Anderson C, Bonomi P, Harris J. MK 886 functions as a radiomimetic agent: genomic responses related to oxidative stress, the cell cycle, proliferation and programmed cell death in Panc-1 cells. Adv Exp Med Biol. 2002; 507:451-6. PMID: 12664625.
      Citations:    
    113. Bonomi P. Novel approaches for the treatment of non-small cell lung cancer. Semin Oncol. 2001 Aug; 28(4 Suppl 14):45-9. PMID: 11605183.
      Citations:    
    114. Ou D, Bonomi P, Jao W, Jadko S, Harris JE, Anderson KM. The mode of cell death in H-358 lung cancer cells cultured with inhibitors of 5-lipoxygenase or the free radical spin trap, NTBN. Cancer Lett. 2001 May 26; 166(2):223-31. PMID: 11311496.
      Citations:    
    115. Bonomi P, Shirazi W. Chemoradiation in locally advanced non-small cell lung cancer. Cancer Treat Res. 2001; 105:171-88. PMID: 11224987.
      Citations:    
    116. Kucuk O, Shevrin DH, Pandya KJ, Bonomi PD. Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586). Am J Clin Oncol. 2000 Aug; 23(4):371-5. PMID: 10955866.
      Citations:    
    117. Belani CP, Einzig A, Bonomi P, Dobbs T, Capozzoli MJ, Earhart R, Cohen LJ, Luketich JD. Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. Ann Oncol. 2000 Jun; 11(6):673-8. PMID: 10942054.
      Citations:    
    118. Anderson KM, Alrefai WA, Anderson CA, Bonomi P, Harris JE. Widespread countervailing genomic responses induced by chemotherapy or radiation as a cause of therapeutic failure. Med Hypotheses. 2000 Jun; 54(6):1000-2. PMID: 10867755.
      Citations:    
    119. Harrison J, Ali A, Bonomi P, Prinz R. The role of positron emission tomography in selecting patients with metastatic cancer for adrenalectomy. Am Surg. 2000 May; 66(5):432-6; discussion 436-7. PMID: 10824742.
      Citations:    
    120. Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb; 18(3):623-31. PMID: 10653877.
      Citations:    
    121. Gandara DR, Vokes E, Green M, Bonomi P, Devore R, Comis R, Carbone D, Karp D, Belani C. Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol. 2000 Jan; 18(1):131-5. PMID: 10623703.
      Citations:    
    122. Belani CP, Bonomi P, Dobbs TW, DeVore RF, Ettinger DS, Jett J, Luketich JD, Cohen LJ, Johnson DH. Docetaxel and cisplatin in patients with advanced non small-cell lung cancer (NSCLC): a multicenter phase II trial. Clin Lung Cancer. 1999 Nov; 1(2):144-50. PMID: 14733666.
      Citations:    
    123. Tester WJ, Kim KM, Krigel RL, Bonomi PD, Glick JH, Asbury RF, Kirkwood JM, Blum RH, Schiller JH. A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (PZ586). Lung Cancer. 1999 Sep; 25(3):199-206. PMID: 10512131.
      Citations:    
    124. Anderson KM, Alrefai WA, Bonomi P, Dudeja P, Ou D, Anderson C, Harris JE. Altered oncogene, tumor suppressor and cell-cycle gene expression in PANC-1 cells cultured with the pleiotrophic 5-lipoxygenase inhibitor, MK886, assessed with a gene chip. Anticancer Res. 1999 Sep-Oct; 19(5B):3873-87. PMID: 10628326.
      Citations:    
    125. Rowinsky EK, Jiroutek M, Bonomi P, Johnson D, Baker SD. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. Clin Cancer Res. 1999 Apr; 5(4):767-74. PMID: 10213211.
      Citations:    
    126. Ou D, Anderson KM, Leslie W, Bonomi P, Harris JE. Does maximizing programmed cell death necessarily yield an optimum clinical advantage? Med Hypotheses. 1999 Mar; 52(3):235-8. PMID: 10362283.
      Citations:    
    127. Bonomi P. Review of paclitaxel/carboplatin in advanced non-small cell lung cancer. Semin Oncol. 1999 Feb; 26(1 Suppl 2):55-9. PMID: 10190784.
      Citations:    
    128. Anderson KM, Ells G, Bonomi P, Harris JE. Free radical spin traps as adjuncts for the prevention and treatment of disease. Med Hypotheses. 1999 Jan; 52(1):53-7. PMID: 10342672.
      Citations:    
    129. Bonomi P. Review of selected randomized trials in small cell lung cancer. Semin Oncol. 1998 Aug; 25(4 Suppl 9):70-8. PMID: 9728589.
      Citations:    
    130. Fairclough DL, Peterson HF, Cella D, Bonomi P. Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials. Stat Med. 1998 Mar 15-Apr 15; 17(5-7):781-96. PMID: 9549823.
      Citations:    
    131. Anderson KM, Bonomi P, Meng J, Harris JE. Inhibition of cancer cell proliferation by disruption of interdigitated/concatenated hierarchies of metabolic control/implementation processes: a proposal. Med Hypotheses. 1998 Feb; 50(2):119-23. PMID: 9572565.
      Citations:    
    132. Chang AY, Kim K, Boucher H, Bonomi P, Stewart JA, Karp DD, Blum RH. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587). Cancer. 1998 Jan 15; 82(2):292-300. PMID: 9445185.
      Citations:    
    133. Bonomi P. Eastern Cooperative Oncology Group experience with chemotherapy in advanced non-small cell lung cancer. Chest. 1998 Jan; 113(1 Suppl):13S-16S. PMID: 9438684.
      Citations:    
    134. Johnson DH, Chang AY, Ettinger DS, Kim KM, Bonomi P. Recent advances with chemotherapy for NSCLC: the ECOG experience. Eastern Cooperative Oncology Group. Oncology (Williston Park). 1998 Jan; 12(1 Suppl 2):67-70. PMID: 9516615.
      Citations:    
    135. Bonomi P, Faber LP, Warren W, Lincoln S, LaFollette S, Sharma M, Recine D. Postoperative bronchopulmonary complications in stage III lung cancer patients treated with preoperative paclitaxel-containing chemotherapy and concurrent radiation. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-123-S12-129. PMID: 9331136.
      Citations:    
    136. Johnson D, Arriagada R, Barthelemy N, Bonner J, Bonomi P, Enami B, Minatel E, Park K, Quoix E, Van Houtte P. Post-operative adjuvant therapy for non-small-cell lung cancer. Lung Cancer. 1997 Jun; 17 Suppl 1:S23-5. PMID: 9213299.
      Citations:    
    137. Bonomi P, Kim K, Kusler J, Johnson D. Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer. Oncology (Williston Park). 1997 Apr; 11(4 Suppl 3):9-10. PMID: 9144683.
      Citations:    
    138. Preisler HD, Raza A, Bonomi P, Taylor S, LaFolette S, Leslie W, Lincoln S. Regrowth resistance as a likely significant contributor to treatment failure in drug-sensitive neoplastic diseases. Cancer Invest. 1997; 15(4):358-68. PMID: 9246159.
      Citations:    
    139. Buyn T, Dudeja P, Harris JE, Ou D, Seed T, Sawlani D, Meng J, Bonomi P, Anderson KM. A 5-lipoxygenase inhibitor at micromolar concentration raises intracellular calcium in U937 cells prior to their physiologic cell death. Prostaglandins Leukot Essent Fatty Acids. 1997 Jan; 56(1):69-77. PMID: 9044439.
      Citations:    
    140. Bonomi P, Siddiqui S, Lincoln S, Sharma M, Recine D, Warren W, Faber LP. Escalating paclitaxel doses combined with carboplatin/etoposide and thoracic radiotherapy as preoperative or definitive treatment for stage III non-small cell lung cancer. Semin Oncol. 1996 Dec; 23(6 Suppl 16):102-7. PMID: 9007134.
      Citations:    
    141. Lara PN, Bonomi PD, Faber LP. Retreatment of recurrent invasive thymoma with platinum, doxorubicin, and cyclophosphamide. Chest. 1996 Oct; 110(4):1115-7. PMID: 8874280.
      Citations:    
    142. Anderson KM, Seed T, Jajeh A, Dudeja P, Byun T, Meng J, Ou D, Bonomi P, Harris JE. An in vivo inhibitor of 5-lipoxygenase, MK886, at micromolar concentration induces apoptosis in U937 and CML cells. Anticancer Res. 1996 Sep-Oct; 16(5A):2589-99. PMID: 8917356.
      Citations:    
    143. Anderson KM, Bonomi P, Harris JE. Does an inability to eradicate normal stem cells preclude the cure of some cancers? Med Hypotheses. 1996 Jul; 47(1):31-4. PMID: 8819113.
      Citations:    
    144. Buzdar AU, Smith R, Vogel C, Bonomi P, Keller AM, Favis G, Mulagha M, Cooper J. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. Cancer. 1996 Jun 15; 77(12):2503-13. PMID: 8640699.
      Citations:    
    145. Bonomi P, Faber LP, Recine D, Lincoln S. Carboplatin/etoposide/radiation plus escalating doses of paclitaxel in stage III non-small cell lung cancer: a preliminary report. Semin Oncol. 1995 Aug; 22(4 Suppl 9):42-7. PMID: 7644927.
      Citations:    
    146. Wolff AC, Ettinger DS, Neuberg D, Comis RL, Ruckdeschel JC, Bonomi PD, Johnson DH. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol. 1995 Jul; 13(7):1615-22. PMID: 7602350.
      Citations:    
    147. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995 Jun; 12(3):199-220. PMID: 7655830.
      Citations:    
    148. Bonomi P. Combined modality treatment for stage III non-small cell lung cancer. Lung Cancer. 1995 Jun; 12 Suppl 2:S41-52. PMID: 7551949.
      Citations:    
    149. Chang AY, Tu ZN, Smith JL, Bonomi P, Smith TJ, Wiernik PH, Blum R. Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. An Eastern Cooperative Oncology Group study (E2588). Invest New Drugs. 1995; 13(2):137-41. PMID: 8617576.
      Citations:    
    150. Anderson KM, Harris JE, Bonomi P. Potential applications of apoptosis in modifying the biological behavior of therapeutically refractory cancers. Med Hypotheses. 1994 Oct; 43(4):207-13. PMID: 7838002.
      Citations:    
    151. Bonomi P. Treatment of stage III non-small cell lung cancer with thoracic radiation therapy and simultaneous platinum chemotherapy. Semin Oncol. 1994 Jun; 21(3 Suppl 6):101-8. PMID: 8052869.
      Citations:    
    152. Bonomi P, Finkelstein D, Chang A. Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer. An Eastern Cooperative Oncology Group study. Am J Clin Oncol. 1994 Jun; 17(3):215-7. PMID: 8192104.
      Citations:    
    153. Taylor MA, Reddy S, Lee MS, Bonomi P, Taylor SG, Kaplan E, Faber PL, Warren W, Hendrickson FR. Combined modality treatment using BID radiation for locally advanced non-small cell lung carcinoma. Cancer. 1994 May 15; 73(10):2599-606. PMID: 8174058.
      Citations:    
    154. Kayser K, Liewald F, Kremer K, Tacke M, Storck M, Faber P, Bonomi P. Alteration of integrated optical density and intercellular structure after induction chemotherapy and survival in lung carcinoma patients treated surgically. Anal Quant Cytol Histol. 1994 Feb; 16(1):18-24. PMID: 8011037.
      Citations:    
    155. Bonomi P. Radiation and simultaneous cisplatin in non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1993 Oct 20; 27(3):739-46. PMID: 8226172.
      Citations:    
    156. Bonomi PD, Finkelstein D, Aisner S, Ettinger D. EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma. Am J Clin Oncol. 1993 Aug; 16(4):342-5. PMID: 8328413.
      Citations:    
    157. Johnson DH, Turrisi AT, Chang AY, Blum R, Bonomi P, Ettinger D, Wagner H. Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group. J Clin Oncol. 1993 May; 11(5):879-84. PMID: 8387577.
      Citations:    
    158. Ettinger DS, Finkelstein DM, Abeloff MD, Skeel RT, Stott PB, Frontiera MS, Bonomi PD. Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study. J Natl Cancer Inst. 1992 Jul 15; 84(14):1077-84. PMID: 1320131.
      Citations:    
    159. Bonomi P. Platinum/etoposide therapy in non-small cell lung cancer. Oncology. 1992; 49 Suppl 1:43-50. PMID: 1323811.
      Citations:    
    160. Reddy S, Lee MS, Bonomi P, Taylor SG, Kaplan E, Gale M, Faber LP, Warren W, Kittle CF, Hendrickson FR. Combined modality therapy for stage III non-small cell lung carcinoma: results of treatment and patterns of failure. Int J Radiat Oncol Biol Phys. 1992; 24(1):17-23. PMID: 1324896.
      Citations:    
    161. Thomas CR, Bonomi PD. Mediastinal tumors. Curr Opin Oncol. 1991 Apr; 3(2):335-43. PMID: 1648973.
      Citations:    
    162. Bonomi P. Carboplatin in non-small cell lung cancer: review of the Eastern Cooperative Oncology Group trial and comparison with other carboplatin trials. Semin Oncol. 1991 Feb; 18(1 Suppl 2):2-7. PMID: 1846979.
      Citations:    
    163. Bonomi P, Gale M, Rowland K, Taylor SG, Purl S, Reddy S, Lee MS, Phillips A, Kittle CF, Warren W, et al. Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment. Int J Radiat Oncol Biol Phys. 1991 Feb; 20(2):247-52. PMID: 1846847.
      Citations:    
    164. Bonomi PD, Gale M, Faber LP, Reddy S. Prognostic importance of subdividing clinically staged IIIa and IIIb patients with non-small-cell lung cancer. J Clin Oncol. 1991 Feb; 9(2):357-9. PMID: 1846408.
      Citations:    
    165. Bonomi P. Recent advances in etoposide therapy for non-small cell lung cancer. Cancer. 1991 Jan 01; 67(1 Suppl):254-9. PMID: 1845849.
      Citations:    
    166. Bonomi P, Reddy S, Faber LP. Concurrent chemotherapy and thoracic irradiation in non-small cell lung cancer. Hematol Oncol Clin North Am. 1990 Dec; 4(6):1143-58. PMID: 1962781.
      Citations:    
    167. Recine D, Rowland K, Reddy S, Lee MS, Bonomi P, Taylor S, Faber LP, Warren W, Kittle CF, Hendrickson FR. Combined modality therapy for locally advanced non-small cell lung carcinoma. Cancer. 1990 Dec 01; 66(11):2270-8. PMID: 2173969.
      Citations:    
    168. Heaton D, Yordan E, Reddy S, Bonomi P, Lee MS, Lincoln S, Graham J, Dolan T, Miller A, Phillips A, et al. Treatment of 29 patients with bulky squamous cell carcinoma of the cervix with simultaneous cisplatin, 5-fluorouracil, and split-course hyperfractionated radiation therapy. Gynecol Oncol. 1990 Sep; 38(3):323-7. PMID: 2227542.
      Citations:    
    169. Reddy S, Faber LP, Baumann LA, Lee MS, Jensik RJ, Kittle FC, Bonomi PD, Taylor SG, Hendrickson FR. Preoperative radiation therapy in regionally localized stage III non-small cell lung carcinoma: long-term results and patterns of failure. Int J Radiat Oncol Biol Phys. 1990 Aug; 19(2):287-92. PMID: 2168353.
      Citations:    
    170. Thomas CR, Bonomi P. Mediastinal tumors. Curr Opin Oncol. 1990 Apr; 2(2):359-67. PMID: 2095247.
      Citations:    
    171. Faber LP, Bonomi PD. Neoadjuvant treatment in locally advanced non-small cell lung cancer. Semin Surg Oncol. 1990; 6(5):255-62. PMID: 2173096.
      Citations:    
    172. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Comis R, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol. 1989 Nov; 7(11):1602-13. PMID: 2553879.
      Citations:    
    173. Bonomi P, Blessing J, Ball H, Hanjani P, DiSaia PJ. A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol. 1989 Sep; 34(3):357-9. PMID: 2767528.
      Citations:    
    174. Faber LP, Kittle CF, Warren WH, Bonomi PD, Taylor SG, Reddy S, Lee MS. Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann Thorac Surg. 1989 May; 47(5):669-75; discussion 676-7. PMID: 2543340.
      Citations:    
    175. Staren ED, Gould VE, Warren WH, Wool NL, Bines S, Baker J, Bonomi P, Roseman DL, Economou SG. Neuroendocrine carcinomas of the colon and rectum: a clinicopathologic evaluation. Surgery. 1988 Dec; 104(6):1080-9. PMID: 3194834.
      Citations:    
    176. Finkelstein DM, Cassileth BR, Bonomi PD, Ruckdeschel JC, Ezdinli EZ, Wolter JM. A pilot study of the Functional Living Index-Cancer (FLIC) Scale for the assessment of quality of life for metastatic lung cancer patients. An Eastern Cooperative Oncology Group study. Am J Clin Oncol. 1988 Dec; 11(6):630-3. PMID: 3055933.
      Citations:    
    177. Pincus M, Reddy S, Lee MS, Bonomi P, Taylor S, Rowland K, Faber LP, Warren W, Kittle CF, Hendrickson FR. Preoperative combined modality therapy for stage III M0 non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 1988 Jul; 15(1):189-95. PMID: 2839440.
      Citations:    
    178. Johnson PA, Muss H, Bonomi P, Von Roenn J, Wolter J, Paschold E, Black W, Cooper M. Megestrol acetate as primary hormonal therapy for advanced breast cancer. Semin Oncol. 1988 Apr; 15(2 Suppl 1):34-7. PMID: 3368798.
      Citations:    
    179. Rizk SL, Roseman DL, Bonomi P, Sky-Peck H, Clark J, Lee I, Gould VE. Elevated creatine phosphokinase MB in a patient with neuroendocrine carcinoma of the colon--evidence for a tumor marker. Report of a case. Dis Colon Rectum. 1988 Apr; 31(4):318-22. PMID: 3359901.
      Citations:    
    180. Bonomi P, Gale M, Von Roenn J, Anderson K, Johnson P, Wolter J, Economou S. Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen. Semin Oncol. 1988 Apr; 15(2 Suppl 1):26-33. PMID: 3368797.
      Citations:    
    181. Von Roenn JH, Bonomi PD, Gale M, Anderson KM, Wolter JM, Economou SG. Sequential hormone therapy for advanced breast cancer. Semin Oncol. 1988 Apr; 15(2 Suppl 1):38-43. PMID: 3368799.
      Citations:    
    182. Bonomi P, Yordan E, Blessing JA. Phase I trial of cisplatin and razoxane (ICRF-159) (NSC #119875) in advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Pilot Study. Am J Clin Oncol. 1988 Feb; 11(1):1-2. PMID: 3277372.
      Citations:    
    183. Rowland KM, Bonomi P, Taylor SG, Maffey S, Reddy S, Lee MS. Continuous infusion of etoposide, bolus administration of cisplatin, and simultaneous radiation therapy in previously treated patients with small cell bronchogenic carcinoma. NCI Monogr. 1988; (6):323-5. PMID: 2832766.
      Citations:    
    184. Taylor SG, Murthy AK, Bonomi P, Reddy S, Lee MS, Faber LP, Mathisen DJ. Concomitant therapy with infusion of cisplatin and 5-fluorouracil plus radiation in stage III non-small cell lung cancer. NCI Monogr. 1988; (6):327-9. PMID: 2832767.
      Citations:    
    185. Bonomi P, Rowland KM, Taylor SG, Pincus M, Reddy S, Lee MS, Faber LP, Warren W, Kittle CF. Phase II trial of therapy with etoposide, 5-fluorouracil by continuous infusion, cisplatin, and simultaneous split-course radiation in stage III non-small cell bronchogenic carcinoma. NCI Monogr. 1988; (6):331-4. PMID: 2832768.
      Citations:    
    186. Braun DP, Bonomi PD, Taylor SG, Harris JE. Modification of the effects of cytotoxic chemotherapy on the immune responses of cancer patients with a nonsteroidal, antiinflammatory drug, piroxicam. A pilot study of the Eastern Cooperative Oncology Group. J Biol Response Mod. 1987 Jun; 6(3):331-45. PMID: 3037033.
      Citations:    
    187. Bhatia SK, Saclarides TJ, Witt TR, Bonomi PD, Anderson KM, Economou SG. Hormone receptor studies in axillary metastases from occult breast cancers. Cancer. 1987 Mar 15; 59(6):1170-2. PMID: 3815292.
      Citations:    
    188. Taylor SG, Trybula M, Bonomi PD, Faber LP, Lee MS, Reddy S, Maffey SC, Mathisen DJ, Jensik RJ, Kittle CF. Simultaneous cisplatin fluorouracil infusion and radiation followed by surgical resection in regionally localized stage III, non-small cell lung cancer. Ann Thorac Surg. 1987 Jan; 43(1):87-91. PMID: 3026263.
      Citations:    
    189. Ettinger DS, Allegra J, Bertino JR, Bonomi P, Browder H, Byrne P, Carpenter J, Catalano R, Creech R, Dana B, et al. Megestrol acetate v tamoxifen in advanced breast cancer: correlation of hormone receptors and response. Semin Oncol. 1986 Dec; 13(4 Suppl 4):9-14. PMID: 3026052.
      Citations:    
    190. Johnson PA, Bonomi PD, Anderson KM, Wolter JM, Economou SG. Megestrol acetate: first-line therapy for advanced breast cancer. Semin Oncol. 1986 Dec; 13(4 Suppl 4):15-9. PMID: 3798124.
      Citations:    
    191. Bonomi PD, Pazdur R, Stolbach L, Mason B, Ettinger D. Phase II trial of mitomycin, vindesine, and hexamethylmelamine in metastatic non-small cell bronchogenic carcinoma. Cancer Treat Rep. 1986 Dec; 70(12):1447-8. PMID: 3024827.
      Citations:    
    192. Bonomi P, Rowland K, Taylor SG, Reddy S, Lee MS, Faber LP, Warren W. Phase II trial of etoposide, cisplatin, continuous infusion 5-fluorouracil, and simultaneous split-course radiation therapy in stage III non-small-cell bronchogenic carcinoma. Semin Oncol. 1986 Sep; 13(3 Suppl 3):115-20. PMID: 3764446.
      Citations:    
    193. Bonomi P. Brief overview of combination chemotherapy in non-small-cell lung cancer. Semin Oncol. 1986 Sep; 13(3 Suppl 3):89-91. PMID: 3020706.
      Citations:    
    194. Harris J, Das Gupta T, Vogelzang N, Badrinath K, Bonomi P, Desser R, Locker G, Blough R, Johnson C. Treatment of soft tissue sarcoma with fibroblast interferon (beta-interferon): an American Cancer Society/Illinois Cancer Council Study. Cancer Treat Rep. 1986 Feb; 70(2):293-4. PMID: 3948193.
      Citations:    
    195. Allegra JC, Bertino J, Bonomi P, Byrne P, Carpenter J, Catalano R, Creech R, Dana B, Durivage H, Einhorn L, et al. Metastatic breast cancer: preliminary results with oral hormonal therapy. Semin Oncol. 1985 Dec; 12(4 Suppl 6):61-4. PMID: 3909420.
      Citations:    
    196. Bonomi P, O'Reilly W, Vogl SE, Ruckdeschel JC, Stolbach L, Bunting N, Creech RH. Intensive induction treatment of small cell bronchogenic carcinoma with cyclophosphamide, methotrexate, and etoposide. Cancer Treat Rep. 1985 Sep; 69(9):1007-9. PMID: 2992783.
      Citations:    
    197. Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L, Major FJ. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1985 Aug; 3(8):1079-85. PMID: 3894589.
      Citations:    
    198. Bonomi P, Johnson P, Anderson K, Wolter J, Bunting N, Strauss A, Roseman D, Shorey W, Economou S. Primary hormonal therapy of advanced breast cancer with megestrol acetate: predictive value of estrogen receptor and progesterone receptor levels. Semin Oncol. 1985 Mar; 12(1 Suppl 1):48-54. PMID: 3975653.
      Citations:    
    199. Bonomi P, Pessis D, Bunting N, Block M, Anderson K, Wolter J, Rossof A, Slayton R, Harris J. Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer. Semin Oncol. 1985 Mar; 12(1 Suppl 1):36-9. PMID: 3975650.
      Citations:    
    200. Loehrer PJ, Bonomi P, Goldman S, Reddy S, Faber LP, Jensik R, Dainauskas JR. Remission of invasive thymoma due to chemotherapy. Two patients treated with cyclophosphamide, doxorubicin, and vincristine. Chest. 1985 Mar; 87(3):377-80. PMID: 3971764.
      Citations:    
    201. Kirkwood JM, Harris JE, Vera R, Sandler S, Fischer DS, Khandekar J, Ernstoff MS, Gordon L, Lutes R, Bonomi P, et al. A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res. 1985 Feb; 45(2):863-71. PMID: 3881175.
      Citations:    
    202. Anderson KM, Bonomi P. Metastatic breast cancer from an occult primary provisionally identified by steroid receptor content and two-dimensional protein electrophoresis: some problems associated with the use of the latter technique. Clin Physiol Biochem. 1985; 3(5):265-70. PMID: 4053492.
      Citations:    
    203. Anderson KM, Baranowski J, Bonomi P, Economou SG. Qualitative analysis of Coomassie-blue-stained proteins from normal prostate, benign prostatic hypertrophy, or adenocarcinoma of the prostate, separated by two-dimensional protein electrophoresis. Prostate. 1985; 6(3):315-23. PMID: 2581237.
      Citations:    
    204. Sandler S, Bonomi P, Taylor B, Showel J, Slayton R, Lerner H. Doxorubicin and cisplatin for recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer Treat Rep. 1984 Sep; 68(9):1163-5. PMID: 6541095.
      Citations:    
    205. Tom?s-de la Vega JE, Donahue EJ, Doolas A, Roseman DL, Straus A, Bonomi PD, Economou SG. A ten year experience with hepatic resection. Surg Gynecol Obstet. 1984 Sep; 159(3):223-8. PMID: 6474324.
      Citations:    
    206. Gould VE, Jao W, Chejfec G, Banner BF, Bonomi P. Neuroendocrine carcinomas of the gastrointestinal tract. Semin Diagn Pathol. 1984 Feb; 1(1):13-8. PMID: 6400627.
      Citations:    
    207. Johnson PA, Bonomi PD, Anderson KM, Wolter JM, Bacon LD, Rossof AH, Economou SG. Progesterone receptor level as a predictor of response to megestrol acetate in advanced breast cancer: a retrospective study. Cancer Treat Rep. 1983 Jul-Aug; 67(7-8):717-20. PMID: 6871887.
      Citations:    
    208. Bonomi P, Blessing JA, Sedlacek TV, Homesley HD, DiSaia PJ. Phase II trial of AMSA in patients with advanced or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. Cancer Treat Rep. 1983 Feb; 67(2):197-8. PMID: 6687445.
      Citations:    
    209. Anderson KM, Baranowski J, Bonomi P, Economou SG. Provisional "normograms" for identifying adenocarcinomas of the prostate or colon and hepatocellular carcinoma derived from their distribution of proteins separated by two-dimensional electrophoresis. Prostate. 1983; 4(1):83-9. PMID: 6300817.
      Citations:    
    210. Creech RH, Stanley K, Vogl SE, Ettinger DS, Bonomi PD, Salazar O. Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578). Cancer Treat Rep. 1982 Jun; 66(6):1417-9. PMID: 6282460.
      Citations:    
    211. Pazdur R, Rossof AH, Chandra G, Bonomi PD, Slayton RE, Wolter J. Vindesine: phase II evaluation in colon cancer and description of its platelet stimulating activity. Cancer Chemother Pharmacol. 1982; 9(1):41-4. PMID: 7139851.
      Citations:    
    212. Pazdur R, Bonomi P, Slayton R, Gould VE, Miller A, Jao W, Dolan T, Wilbanks G. Neuroendocrine carcinoma of the cervix: implications for staging and therapy. Gynecol Oncol. 1981 Aug; 12(1):120-8. PMID: 6268485.
      Citations:    
    213. Mitsuyasu R, Bonomi P, Anderson K, Fischer W. Response to megestrol in male breast carcinoma. Arch Intern Med. 1981 May; 141(6):809-10. PMID: 6263202.
      Citations:    
    214. Pazdur R, Bonomi P, Gould VE, Yordan E, Roseman D, Holinger L, Kittle CF. Neuroendocrine small cell carcinomas in miscellaneous primary sites: implications for staging and therapy. Anticancer Res. 1981; 1(6):335-40. PMID: 6284016.
      Citations:    
    215. Block M, Bonomi P, Anderson K, Wolter J, Showel J, Pessis D, Slayton R. Treatment of stage D prostatic carcinoma with megestrol acetate. J Surg Oncol. 1981; 17(4):367-71. PMID: 7265976.
      Citations:    
    216. Anderson KM, Bonomi P, Marogil M, Hendrickson C, Economou S. Comparison of dextran-coated charcoal and sucrose density gradient analyses of estrogen and progesterone receptors in human breast cancer. Cancer Res. 1980 Nov; 40(11):4127-32. PMID: 6162545.
      Citations:    
    217. Anderson KM, Marogil M, Bonomi PD, Hendrickson C, Economou S. Stabilization of human breast cancer progesterone (5020) receptor by sodium molybdate. Clin Chim Acta. 1980 May 09; 103(3):367-73. PMID: 7398079.
      Citations:    
    Bonomi's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (526)
    Explore
    _
    Co-Authors (14)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _